Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 4/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919799 | 0.76 | SIGMAR1 (0.42) | GAAMAPTTSHRALDH1A1TP53 | |
| SCHEMBL5642052 | 0.76 | MAPT (0.55) | GAAMAPTTSHRALDH1A1TP53 | |
| SCHEMBL17223782 | 0.75 | GAA (0.38) | GAAMAPTTSHRALDH1A1TP53 | |
| SCHEMBL13451052 | 0.74 | GAA (0.52) | GAAMAPTTSHRALDH1A1TP53 | |
| SCHEMBL9686484 | 0.74 | SIGMAR1 (0.32) | GAAALDH1A1KDM4ELMNAPARP1 | |
| SCHEMBL28085048 | 0.71 | GAA (0.38) | GAAMAPTTSHRALDH1A1TP53 | |
| SCHEMBL11174076 | 0.69 | MYC (0.36) | MAPTALDH1A1TP53KDM4EMAPK1 | |
| SCHEMBL1116304 | 0.69 | CYP3A4 (0.36) | GAAMAPTTSHRALDH1A1TP53 | |
| SCHEMBL1116324 | 0.69 | KDM4E (0.43) | GAAMAPTTSHRALDH1A1TP53 | |
| SCHEMBL11543026 | 0.69 | GABRA1 (0.38) | GAAMAPTTSHRALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | ESSER FRANZ (DE) | 2002-04-04 | — | — | US | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | GAA 1320/4885MAPT 2876/4885TSHR 2606/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | GAA 907/4885MAPT 2124/4885TSHR 4526/4885 |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | COL1A1, TPSAB1, TACR1 | GAA 1011/4885MAPT 875/4885TSHR 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.